Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.03 | $0 | -$969,999 |
| 2026 Q1 | -0.05 | $0 | -$2M |
| 2025 Q4 | -0.30 | $0 | -$386,850 |
| 2025 Q3 | -0.07 | $0 | -$613,720 |
| 2025 Q2 | 0.00 | $0 | -$9M |
| 2025 Q1 | -2.55 | $0 | -$159,393 |
| 2024 Q4 |
| -0.12 |
| $0 |
| -$140,660 |
| 2024 Q3 | -0.09 | $0 | -$729,360 |